Lenalidomide Capsule
Product Images NDC 60505-4532

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Lenalidomide (NDC 60505-4532). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Apotex Corp., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure1.jpg (Figure1)

This is a survival analysis of three groups: Rd Continuous, Rd18, and MPT. The graph shows the progression-free survival (in months) on the x-axis and the survival probability percentage on the y-axis. The survival probability is shown for each group at different time points. The table below shows the hazard ratio (HR) with 95% confidence interval (CI) and the logrank p-value (2-sided) for each comparison between groups. The number of subjects at risk and PFS events are also provided.*

FDA Label Image

Figure2.jpg (Figure2)

FDA Label Image

Figure3.jpg (Figure3)

The text seems to be a presentation slide or graph showing the proportion of subjects in a study comparing the drugs Lenalidomide/Dex versus Placebo/Dex. The graph also displays the hazard ratio (HR) and confidence interval (95% CI) for the study along with the Log Rank p-value for statistical significance. Additionally, the graph displays the time to progression (in months) for the two treatments.*

FDA Label Image

Figure4.jpg (Figure4)

This appears to be a statistical analysis or result presentation of a medical research study comparing the efficacy of Lenalidomide/Dex versus Placebo/Dex in terms of time to progression, with detailed information on proportion of subjects in the study and HR (Hazard ratio) with its confidence interval and Log Rank p value.*

FDA Label Image

Figure5.jpg (Figure5)

This is a comparison of the effectiveness of Lenalidomide versus a placebo (Plactbo) for Progression-free Survival (PFS) in a group of subjects. The data shows the PFS on the vertical axis against time (in months) on the horizontal axis, with a lower hazard ratio (HR) for Lenalidomide. The median for Lenalidomide is higher (68.6 months) with a wide confidence interval (52.8 to not estimable) compared to a lower median for the placebo treatment (22.5 months), with a smaller confidence interval (18.8 to 30.0). The number of PFS events and subjects at risk for both treatments are shown in a table.*

FDA Label Image

Figure6.jpg (Figure6)

The text appears to be a statistical analysis of the clinical trial data for the drug Lenalidomide versus a placebo with regard to progression-free survival probability over time. It shows a comparison of survival probability curves, hazard ratio, and median progression-free survival time for both groups. The number of subjects at risk and the percentage of PFS events are also reported.*

FDA Label Image

Figure7.jpg (Figure7)

This appears to be a table or chart showing the results of a study comparing the drugs Rituximab and Lenalidomide to Rituximab and Placebo. The table shows the number of subjects at risk, as well as the progression-free survival in months. The results suggest that the combination of Rituximab and Lenalidomide may be more effective than Rituximab and Placebo, with a significant decrease in risk of progression.*

FDA Label Image

Lenalidomide10mg (Lenalidomide10mg)

Each capsule contains 10 mg of ensldomi. Store between 20°C to 25°C (excursions permitted to 15°C to 50°C). The package insert contains the usual dosage information. The medication may cause human birth defects. Dispense the enclosed medication guide to each patient. The product is manufactured and distributed by APOTEX CORP and comes in a container that meets USP standards. The package contains 28 capsules with NDC 60505-4534-2.*

FDA Label Image

Lenalidomide15mg (Lenalidomide15mg)

Each capsule contains 15 mg of enslicomie. The package insert recommends that the pharmacist dispense the accompanying anti-nausea medication guide to each patient. This medication should be stored in a tightly closed container at temperatures between 15°C - 30°C (59 - 86°F). The product is manufactured by Apotex Corp. The packaging contains a warning about the potential for human birth defects. The NDC number for the 21 capsules is 60505-4535-2.*

FDA Label Image

Lenalidomide25mg (Lenalidomide25mg)

Each capsule of this medication contains 25mg of Enslomi and should be stored between 20-25°C (65°F - 77°F) with permitted excursions between 15°C - 0°C (59°F - 86°F). The medication should be dispensed in a tightly closed container along with its medication guide. The recommended dosage should be reviewed on the package insert, and pharmacists ought to include a patient medication guide. The medication is available in 21 capsules and identified by NDC 60505-4537-2. The packaging warns of the potential for human birth defects.*

FDA Label Image

Lenalidomide5mg (Lenalidomide5mg)

Each capsule contains 5mg of enaldomi. Store at 25°C (77°F) with excursions permitted from 15°C to 30°C (59°F to 86°F) as per USP-controlled room temperature. Dispense in a tight container as per USP. Usual dosage as per package insert. Pharmacists should dispense the Ancillary Medication Guide to each patient. Warning: Potential for human birth defects. 28 capsules NDC 60505-4533-2. B.Only APOTEX CORP.*

FDA Label Image

Structure (Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.